Christopher Broder | Professor And Chair
Uniformed Services University | United States

Christopher Broder, Professor And Chair, Uniformed Services University

Christopher C. Broder received his B.S. (1983) and M.S. (1985) degrees from the Florida Institute of Technology, Melbourne. He earned his Ph.D. from the University of Florida, Gainesville (1989) establishing a molecular-pathogenic model for the flesh-eating Group A streptococci. He began his postdoctoral studies in 1989 as a National Research Council Research Associate in the Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, focusing on HIV-1 host cell entry and infection. He joined the faculty of the Department of Microbiology and Immunology at Uniformed Services University (USU) as Assistant Professor in 1996 and rose through the ranks to become a full Professor in 2005. His laboratory has focused on virus-host cell interactions with an emphasis on virus receptor discovery, virus entry and virus-mediated membrane fusion, vaccines and antibody therapeutics development. Research areas include HIV-1 and emerging zoonotic viruses including Nipah virus and Hendra virus; Ebola and Marburg viruses, and bat lyssavirus. His major collaborative research contributions include the discoveries of the CXCR4 and the CCR5 HIV-1 coreceptors (1996-Breakthrough of the Year, Science magazine and the AAAS Newcomb Cleveland Prize 1997); the development of the first oligomeric, HIV-1 soluble gp140 glycoprotein vaccine candidate; discovery of the host cell receptor proteins (ephrin ligands) used by Nipah virus and Hendra virus; development of the Hendra/Nipah soluble G glycoprotein subunit vaccine; one formulation known as Equivac® HeV (Zoetis, Inc.), the first commercialized vaccine against a BSL-4 agent. Clinical development of the Hendra soluble G subunit vaccine is underway by Profectus Biosciences, Inc., and supported by CEPI (The Coalition for Epidemic Preparedness Innovations). Therapeutic antiviral human monoclonal antibodies have also been developed, including the anti-Hendra/Nipah human mAb m102.4 which has been used by emergency protocol in 13 people in Australia and one in the U.S. because of significant risk of Hendra or Nipah virus infection. The m102.4 antibody has completed a Phase I clinical trial in Australia, and has recently been supplied to Government of India and included in an international Nipah treatment protocol sponsored by the Indian Council of Medical Research (ICMR) with support from the NIAID, NIH, USA. He currently serves on the editorial board of five journals, and recent honors include the 2019 and 2013 Federal Laboratory Consortium (FLC) Awards for Excellence in Technology Transfer; the CSIRO Chairman’s Medal for 2013, (Australia's national science agency); the 2014 Cinda Helke Award for Excellence in Graduate Student Advocacy and the 2016 James J. Leonard Award for Excellence in Translational/Clinical Research. He has mentored 13 graduate students and 12 postdoctoral scientists, has coauthored more than 165 scientific articles and book chapters and his work has been cited more 19,400 times and is an inventor on 19 US and foreign patents. He served as Director of the Emerging Infectious Diseases Graduate Program at USU from 2006-2018, and his is currently Professor and Chair of the Department of Microbiology and Immunology, USU.

Appearances:



Oct 31st Day 3 @ 09:55

Bats, horses, pigs, people: One health countermeasures against hendra and nipah viruses

last published: 19/Sep/19 13:06 GMT

back to speakers

Sign Up for Event Updates